Korro Bio, Inc. (KRRO) has a negative trailing P/E of -1.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -93.86%.
Criteria proven by this page:
Overall SharesGrow Score: 50/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -21.2 | 0.00 | -14.49 | 0.00 | - |
| 2018 | -22.4 | 4.25 | -8.90 | 0.00 | - |
| 2019 | -28.8 | 48.99 | 3.23 | 18.68 | - |
| 2020 | -42.9 | -1.22 | 5.91 | 30.75 | - |
| 2021 | -13.5 | 0.15 | 8.72 | 81.08 | - |
| 2022 | -0.8 | 0.00 | -0.50 | 0.00 | - |
| 2023 | -0.9 | 0.01 | 0.44 | 0.00 | - |
| 2024 | -4.1 | 0.05 | 2.12 | 149.54 | - |
| 2025 | -0.6 | -0.02 | 1.46 | 11.77 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-32.27 | $0.00 | $-20.24M | - |
| 2018 | $-30.57 | $0.00 | $-19.17M | - |
| 2019 | $-30.39 | $28.95M | $-18.75M | -64.8% |
| 2020 | $-41.10 | $36.98M | $-26.51M | -71.7% |
| 2021 | $-4.94 | $14.07M | $-21.96M | -156.1% |
| 2022 | $-227.42 | $0.00 | $-58.03M | - |
| 2023 | $-53.08 | $0.00 | $-81.17M | - |
| 2024 | $-9.37 | $2.27M | $-83.58M | -3680.4% |
| 2025 | $-12.48 | $6.39M | $-117.26M | -1834.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-6.50 | $-9.58 – $-3.64 | $2.28M | $2.28M – $2.28M | 7 |
| 2027 | $-6.51 | $-9.21 – $-2.60 | $1.46M | $1.46M – $1.46M | 4 |
| 2028 | $-6.71 | $-13.30 – $-2.16 | $2.7M | $2.7M – $2.7M | 6 |
| 2029 | $-8.08 | $-8.08 – $-8.08 | $10.68M | $10.68M – $10.68M | 4 |
| 2030 | $-8.63 | $-8.63 – $-8.63 | $38.62M | $38.62M – $38.62M | 2 |
